Wide Genetic Testing for Lynch Syndrome Cost Effective
PHILADELPHIA — Genetic testing for Lynch Syndrome has always been the most effective strategy for identifying those at risk for colorectal or endometrial cancer, but cost has been a major hurdle. New findings in Cancer Prevention Research, a journal of the American Association for Cancer Research, address those questions of cost effectiveness.
The American Association for Cancer Research will host a teleconference on these findings on Thursday, Nov. 18, 2010, at 3:00 p.m. ET. Reporters and other interested parties can participate by using the following information:
- Dial-in (U.S. and Canada): (888) 282-7404
- Dial-in (International): (706) 679-5207
- Access Code: 20084557
AACR President-elect Judy Garber, M.D., M.P.H., director of the Center for Cancer Genetics and Prevention at the Dana-Farber Cancer Institute, will host the teleconference.
The following panelists will also participate in this teleconference:
Heather Hampel, M.S., associate director of the division of human genetics and professor in the department of internal medicine at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Henry Lynch, M.D., professor of medicine and director of the Hereditary Cancer Center at Creighton University School of Medicine in Omaha, Nebraska, who discovered Lynch Syndrome
Randall W. Burt, M.D., professor of medicine and director of prevention and outreach, Huntsman Cancer Institute at the University of Utah, and co-researcher on the paper
Tuan A. Dinh, Ph.D., head of cancer modeling at Archimedes Inc., and developer of the modeling system to calculate anticipated health benefits and cost effectiveness
Stephen Gruber, M.D., Ph.D., M.P.H., director for cancer prevention and control at the University of Michigan Comprehensive Cancer Center, and a lead researcher on the study.
Follow the AACR on Facebook: http://www.facebook.com/aacr.org
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes 32,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. Including Cancer Discovery, the AACR publishes seven major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. AACR journals represented 20 percent of the market share of total citations in 2009. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists.